Clinical Trial: Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

U.S., April 28 -- ClinicalTrials.gov registry received information related to the study (NCT07552324) titled 'Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP' on April 20.

Brief Summary: This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: DHL THL DLBCL - Diffuse Large B Cell Lymphoma

Intervention: DRUG: CL-Pola-R-CHP

R 375 mg/m2 D1 Pola 1.8mg/kg D1 CTX 750mg/m2 D2 ADR 50mg/m2 D2 Pred 60 mg/m2 D2-6 Chi...